search
Back to results

VDR Gene Polymorphisms and Weight Loss in Non-diabetic Overweight and Obese Subjects

Primary Purpose

Overweight, Obesity

Status
Completed
Phase
Not Applicable
Locations
India
Study Type
Interventional
Intervention
diet and exercise
Sponsored by
Diabetes Foundation, India
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Overweight

Eligibility Criteria

20 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • 20-60 yrs
  • BMI ≥ 23 kg/m2

Exclusion Criteria:

  • Type 1 or Type 2 Diabetes.
  • On drugs or meal supplements for weight loss.
  • On calcium and or vitamin D supplement currently or in the previous six months.
  • Have past or current history or family history of renal stones.
  • Have participated in any other investigational drug study in the previous three months.
  • Have any systemic diseases (cardiac, hepatic, endocrine or renal) or taking any kind of treatment more than one month in the last six months.
  • Diagnosed malabsorption (celiac disease, Cohn's, ulcerative colitis) or history suggestive of malabsorption.
  • Have past history of bariatric surgery

Sites / Locations

  • Anoop misra

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Diet and Exercise

Arm Description

Outcomes

Primary Outcome Measures

Body weight (Kg)
weight loss

Secondary Outcome Measures

Genetic polymorphism
BsmI, TaqI, ApaI, FokI

Full Information

First Posted
July 26, 2017
Last Updated
February 3, 2021
Sponsor
Diabetes Foundation, India
Collaborators
Indian Council of Medical Research
search

1. Study Identification

Unique Protocol Identification Number
NCT03386331
Brief Title
VDR Gene Polymorphisms and Weight Loss in Non-diabetic Overweight and Obese Subjects
Official Title
The Influence of Vitamin D Receptor (VDR) Gene Polymorphisms (BsmI, TaqI, ApaI, FokI) on Weight Loss by Diet and Exercise Interventions in Non-diabetic Overweight and Obese Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
February 2019
Overall Recruitment Status
Completed
Study Start Date
March 16, 2016 (Actual)
Primary Completion Date
March 30, 2019 (Actual)
Study Completion Date
March 30, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Diabetes Foundation, India
Collaborators
Indian Council of Medical Research

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a six months intervention study in non-diabetic overweight and obese subjects. Subjects will be counseled for weight loss through diet and exercise. Diet and exercise will be recommended as per the regular norms for weight loss (weight loss ≥10% from baseline weight will be considered as a significant loss of weight) for overweight and obese subjects. A sample size of 90 subjects was calculated but assuming a drop out rate of 20%, 110 subjects will be enrolled. Enrolled subjects will be measured at every visit (monthly) for weight, body composition measures of abdominal obesity and skin folds. They would be assessed for compliance with diet and exercise. Detailed analysis of body composition including DXA, biochemical analysis will be performed at enrollment and after six months intervention. Statistical analysis will be performed to find association between measures of body composition for weight loss and genotypes of the VDR polymorphisms.
Detailed Description
This is a six months intervention study in non-diabetic overweight and obese subjects. Subjects will be counseled for weight loss through diet and exercise. Diet and exercise will be recommended as per the regular norms for weight loss (weight loss ≥10% from baseline weight will be considered as a significant loss of weight) for overweight and obese subjects. A sample size of 90 subjects was calculated but assuming a drop out rate of 20%, 110 subjects will be enrolled. Enrolled subjects will be measured at every visit (monthly) for weight, body composition measures of abdominal obesity and skin folds. They would be assessed for compliance with diet and exercise. Detailed analysis of body composition including DXA, biochemical analysis will be performed at enrollment and after six months intervention. Statistical analysis will be performed to find association between measures of body composition for weight loss and genotypes of the VDR polymorphisms. VDR Polymorphisms Polymorphisms in the VDR gene have been identified through out the complete VDR gene region and associated with cancer and autoimmune diseases. The FokI polymorphism is present in the translation site and results in the VDR protein being shortened by three amino acids and is not linked with any other VDR polymorphisms. This polymorphism predisposes to bone-disease, risk of cancer, immune mediated diseases 147-149,150, 151. The common VDR gene polymorphisms are BsmI, TaqI, ApaI and FokI. These polymorphisms have shown varying results with insulin sensitivity and secretion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overweight, Obesity

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
110 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Diet and Exercise
Arm Type
Other
Intervention Type
Behavioral
Intervention Name(s)
diet and exercise
Intervention Description
Diet and lifestyle intervention
Primary Outcome Measure Information:
Title
Body weight (Kg)
Description
weight loss
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Genetic polymorphism
Description
BsmI, TaqI, ApaI, FokI
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 20-60 yrs BMI ≥ 23 kg/m2 Exclusion Criteria: Type 1 or Type 2 Diabetes. On drugs or meal supplements for weight loss. On calcium and or vitamin D supplement currently or in the previous six months. Have past or current history or family history of renal stones. Have participated in any other investigational drug study in the previous three months. Have any systemic diseases (cardiac, hepatic, endocrine or renal) or taking any kind of treatment more than one month in the last six months. Diagnosed malabsorption (celiac disease, Cohn's, ulcerative colitis) or history suggestive of malabsorption. Have past history of bariatric surgery
Facility Information:
Facility Name
Anoop misra
City
New Delhi
Country
India

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

VDR Gene Polymorphisms and Weight Loss in Non-diabetic Overweight and Obese Subjects

We'll reach out to this number within 24 hrs